These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 24222773)

  • 1. Biodistribution of mesenchymal stem/stromal cells in a preclinical setting.
    Sensebé L; Fleury-Cappellesso S
    Stem Cells Int; 2013; 2013():678063. PubMed ID: 24222773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of mesenchymal stromal/stem cells according to good manufacturing practices: a review.
    Sensebé L; Gadelorge M; Fleury-Cappellesso S
    Stem Cell Res Ther; 2013 Jun; 4(3):66. PubMed ID: 23751270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo safety profile and biodistribution of GMP-manufactured human skin-derived ABCB5-positive mesenchymal stromal cells for use in clinical trials.
    Tappenbeck N; Schröder HM; Niebergall-Roth E; Hassinger F; Dehio U; Dieter K; Kraft K; Kerstan A; Esterlechner J; Frank NY; Scharffetter-Kochanek K; Murphy GF; Orgill DP; Beck J; Frank MH; Ganss C; Kluth MA
    Cytotherapy; 2019 May; 21(5):546-560. PubMed ID: 30878384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Good manufacturing practices production of mesenchymal stem/stromal cells.
    Sensebé L; Bourin P; Tarte K
    Hum Gene Ther; 2011 Jan; 22(1):19-26. PubMed ID: 21028982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upstream Process Protocol for MSCs Isolated from Different Human-Based Tissue Origins.
    Kılıç P; Özdemir C; Coşar B; Savran BN; Sarıkaya A; Sargon B; Toprakkale A; Songür İ; Kandemir Seçgin Ö; Akpınar Oktar P; Çetindağ EN; Yurtsever Sarıca D; Taşdelen S; Ezer Ü; Kürekçi AE; Gürman G
    Methods Mol Biol; 2024 Jul; ():. PubMed ID: 38967911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome.
    Fernández-Santos ME; Garcia-Arranz M; Andreu EJ; García-Hernández AM; López-Parra M; Villarón E; Sepúlveda P; Fernández-Avilés F; García-Olmo D; Prosper F; Sánchez-Guijo F; Moraleda JM; Zapata AG
    Front Immunol; 2022; 13():918565. PubMed ID: 35812460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety Profile of Good Manufacturing Practice Manufactured Interferon γ-Primed Mesenchymal Stem/Stromal Cells for Clinical Trials.
    Guess AJ; Daneault B; Wang R; Bradbury H; La Perle KMD; Fitch J; Hedrick SL; Hamelberg E; Astbury C; White P; Overolt K; Rangarajan H; Abu-Arja R; Devine SM; Otsuru S; Dominici M; O'Donnell L; Horwitz EM
    Stem Cells Transl Med; 2017 Oct; 6(10):1868-1879. PubMed ID: 28887912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissecting the Pharmacodynamics and Pharmacokinetics of MSCs to Overcome Limitations in Their Clinical Translation.
    Salvadori M; Cesari N; Murgia A; Puccini P; Riccardi B; Dominici M
    Mol Ther Methods Clin Dev; 2019 Sep; 14():1-15. PubMed ID: 31236426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective.
    Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N
    Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Culture and Use of Mesenchymal Stromal Cells in Phase I and II Clinical Trials.
    Philippe B; Luc S; Valérie PB; Jérôme R; Alessandra BR; Louis C
    Stem Cells Int; 2010 Oct; 2010():503593. PubMed ID: 21052537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Regulations for the Production of Multipotent Mesenchymal Stromal Cells for Clinical Application.
    Slaper-Cortenbach IC
    Transfus Med Hemother; 2008; 35(4):295-298. PubMed ID: 21512645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ex vivo-expanded highly pure ABCB5
    Kerstan A; Niebergall-Roth E; Esterlechner J; Schröder HM; Gasser M; Waaga-Gasser AM; Goebeler M; Rak K; Schrüfer P; Endres S; Hagenbusch P; Kraft K; Dieter K; Ballikaya S; Stemler N; Sadeghi S; Tappenbeck N; Murphy GF; Orgill DP; Frank NY; Ganss C; Scharffetter-Kochanek K; Frank MH; Kluth MA
    Cytotherapy; 2021 Feb; 23(2):165-175. PubMed ID: 33011075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivated Platelet Lysate Supports the Proliferation and Immunomodulant Characteristics of Mesenchymal Stromal Cells in GMP Culture Conditions.
    Mareschi K; Castiglia S; Adamini A; Rustichelli D; Marini E; Banche Niclot AGS; Bergallo M; Labanca L; Ferrero I; Fagioli F
    Biomedicines; 2020 Jul; 8(7):. PubMed ID: 32708843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translation of a standardized manufacturing protocol for mesenchymal stromal cells: A systematic comparison of validation and manufacturing data.
    Rojewski MT; Lotfi R; Gjerde C; Mustafa K; Veronesi E; Ahmed AB; Wiesneth M; Körper S; Sensebé L; Layrolle P; Hellem S; Schrezenmeier H
    Cytotherapy; 2019 Apr; 21(4):468-482. PubMed ID: 30926359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications.
    Zhuang WZ; Lin YH; Su LJ; Wu MS; Jeng HY; Chang HC; Huang YH; Ling TY
    J Biomed Sci; 2021 Apr; 28(1):28. PubMed ID: 33849537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesenchymal Stem Cells as Therapeutics Agents: Quality and Environmental Regulatory Aspects.
    Galvez-Martin P; Sabata R; Verges J; Zugaza JL; Ruiz A; Clares B
    Stem Cells Int; 2016; 2016():9783408. PubMed ID: 27999600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A short-term plastic adherence incubation of the stromal vascular fraction leads to a predictable GMP-compliant cell-product.
    Born S; Dörfel MJ; Hartjen P; Haschemi Yekani SA; Luecke J; Meutsch JK; Westphal JK; Birkelbach M; Köhnke R; Smeets R; Krueger M
    Bioimpacts; 2019; 9(3):161-172. PubMed ID: 31508331
    [No Abstract]   [Full Text] [Related]  

  • 18. Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells.
    Leibacher J; Henschler R
    Stem Cell Res Ther; 2016 Jan; 7():7. PubMed ID: 26753925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Automated Large-Scale Production of Paclitaxel Loaded Mesenchymal Stromal Cells for Cell Therapy Applications.
    Lisini D; Nava S; Frigerio S; Pogliani S; Maronati G; Marcianti A; Coccè V; Bondiolotti G; Cavicchini L; Paino F; Petrella F; Alessandri G; Parati EA; Pessina A
    Pharmaceutics; 2020 Apr; 12(5):. PubMed ID: 32365861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Umbilical Cord-Derived Mesenchymal Stem Cells Are Able to Use bFGF Treatment and Represent a Superb Tool for Immunosuppressive Clinical Applications.
    Tesarova L; Jaresova K; Simara P; Koutna I
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32731615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.